Background: Primary hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1) patients with Zollinger-Ellison syndrome (ZES) is caused by parathyroid hyperplasia. Surgery for parathyroid hyperplasia is tricky and difficult. Long-term outcome in ZES/MEN1/HPT is not well known. Methods: Eighty-four consecutive patients (49 F/35 M) with ZES/ MEN1/HPT underwent initial parathyroidectomy (PTX) and were followed at 1-to 3-year intervals. Results: Age at PTX was 36 Ϯ 2 years. Mean follow-up was 17 Ϯ 1 years. Before PTX, mean Ca ϭ 2.8 mmol/L (normal level (nl Ͻ2.5), PTH i ϭ 243 pg/mL (nl Ͻ65), and gastrin ϭ 6950 pg/mL (nl Ͻ 100). Sixty-one percent had nephrolithiasis. Each patient had parathyroid hyperplasia. Fifty-eight percent of patients had 4 parathyroid glands identified. Nine of 84 (11%) had 4 glands removed with immediate autograft, 40/84 (47%) 3 to 3.5 glands, whereas 35/84 (42%) Ͻ3 glands removed. Persistent/recurrent HPT occurred in 42%/48% of patients with Ͻ3 glands, 12%/44% with 3 to 3.5 glands, and 0%/55% with 4 glands removed. Hypoparathyroidism occurred in 3%, 10%, and 22%, respectively. The disease-free interval after surgery was significantly longer if Ͼ3 glands were removed. After surgery to correct the HPT, each biochemical parameter of ZES was improved and 20% of patients no longer had laboratory evidence of ZES. Conclusions: HPT/MEN1/ZES is a severe form of parathyroid hyperplasia with a high rate of nephrolithiasis, persistent and recur-
rent HPT. Surgery to correct the hypercalcemia significantly ameliorates the ZES. Removal of less than 3.5 glands has an unacceptably high incidence of persistent HPT (42%), whereas 4-gland resection and transplant has a high rate of permanent hypoparathyroidism (22%). More than 3-gland resection has a longer diseasefree interval. The surgical procedure of choice for patients with HPT/MEN1/ZES is 3.5-gland parathyroidectomy. Careful long-term follow-up is necessary as a significant proportion will develop recurrent HPT.
(Ann Surg 2008;247: 501-510) P rimary hyperparathyroidism (HPT) is the most common clinical manifestation of multiple endocrine neoplasia type 1 (MEN1). 1, 2 Although there may be asymmetric enlargement of the parathyroid glands causing the surgeon to mistaken the pathology as adenoma, it is always caused by hyperplasia or multiple abnormal parathyroid glands. 3, 4 Surgery to control the HPT in MEN1 patients requires either 3.5-gland parathyroidectomy (PTX) or 4-gland excision with autograft. [5] [6] [7] [8] Patients have a significant rate of persistent HPT with lesser procedures and a high-rate of recurrent HPT as well. 5,9 -13 Careful long-term follow-up studies of these patients are few and the long-term results of surgery have been infrequently reported. Elaraj et al 14 and others 6, [15] [16] [17] have previously focused on the results of initial and reoperations 18 in patients with MEN1 and HPT. This study focuses on a more unique subgroup, those with MEN1, HPT, and Zollinger-Ellison syndrome (ZES). Few previous studies have focused solely on this subgroup, even though ZES occurs in 30% to 70% of all patients with MEN1. 19 ZES is the most common functional pancreatic neuroendocrine syndrome associated with MEN1. 20, 21 It is generally caused by multiple endocrine tumors either within the pancreas or duodenum. Surgery to remove these tumors is seldom curative. 20, 22 Further, in small numbers of cases some groups, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] but not others, 28, 29, [33] [34] [35] [36] have reported an improvement in the laboratory parameters of ZES when surgery is performed to correct the hypercalcemia in MEN1 patients with HPT and ZES. 23 However, because patients with HPT, ZES, and MEN1 are even more rare than those with MEN1 and HPT without ZES, no previous study has carefully examined the precise nature of the parathyroid disease in these patients.
This study carefully characterizes the HPT in patients with HPT, ZES, and MEN1. It reports the long-term results of initial surgery for the HPT in terms of correction of hypercalcemia and the parameters of ZES. The results suggest that the HPT in MEN1 patients with ZES and HPT is more severe than previously reported in routine MEN1/HPT patients and that correction of the hypercalcemia dramatically effects the laboratory parameters of ZES.
METHODS
Since 1980 at the National Institutes of Health (NIH), 84 consecutive patients with ZES, 23, 37, 38 HPT, and MEN1 were included in this analysis. 39 All patients had the diagnosis of HPT confirmed by biochemical studies and signs and symptoms of HPT were especially noted. 19, 23, 40 Elevated serum levels of calcium and intact parathyroid hormone were measured to substantiate the diagnosis of HPT in all patients. Twenty-four hours urinary levels of calcium excretion were also elevated. The diagnosis of ZES was based on acid secretory studies, measurement of fasting serum level of gastrin and the results of secretin, and calcium provocative tests. 37, 38, [41] [42] [43] [44] Basal acid output (BAO) and maximal acid output (MAO) were determined for each patient using methods described previously. 40 Doses of oral gastric antisecretory drug were determined as described previously. 40 A detailed history of disease was taken at first admission including symptoms related to ZES and past medical/surgical procedures as described previously. 39 Time from onset of the disease to exploration was determined for all patients. The time of diagnosis of ZES was the time the diagnosis was first established by appropriate laboratory studies or when a physician established the diagnosis based on clinical presentation.
All patients had the diagnosis of MEN1. MEN1 was established by careful personal and family history, the presence of other tumors associated with MEN1, 19, 45 and assessing plasma hormone levels ͓PTHs (intact, midmolecule), prolactin, insulin, proinsulin, glucagon͔, serum calcium (ionized, total), and glucose that may be abnormal in MEN1. All patients had HPT as diagnosed by elevated serum levels of calcium and parathyroid hormone. Surgery for HPT was done in patients with MEN1, HPT, and ZES over a 35-year period between 1970 and 2005. The operating surgeon had the choice for the type of surgery that was performed. Some of the operations were done at other institutions and the exact protocol was not followed. Operations were performed with the intent to identify all the 4 parathyroid glands, and most consisted of either subtotal (3 or 3.5 glands resected) PTX 7, 14 or a 4-gland PTX with transplant 23 of 20 2 ϫ 1 mm fragments of parathyroid tissue into the nondominant forearm. The cervical thymus was routinely excised for surgical procedures done at the NIH to excise any supernumerary fragments of parathyroid tissue. However, 30% of patients (n ϭ 25) had their initial surgery done elsewhere and cervical thymectomy was not done in those. Intraoperative parathyroid hormone level determinations were not done. 46 Thirty-nine of the patients had surgery performed initially at the NIH and 45 at outside institutions. For these latter patients the results of the surgery were carefully recorded paying special attention to the number of glands removed and total number identified and the preoperative biochemical and hormonal data. In that setting the surgeon may have failed to recognize the extent of HPT or the presence of MEN1 and may have removed less than 3 glands. For the outside surgical MEN1/ZES patients, initially 29 patients had Ͻ3 glands removed, and 16 patients had 3 to 3.5 glands removed.
Postoperatively, NIH patients underwent evaluation for HPT and ZES immediately after surgery, within 3 to 6 months postresection, and then every year thereafter. Yearly evaluations included measuring serum levels of calcium and PTH, acid secretory studies, fasting gastrin determinations, secretin provocative test, and assessment of other endocrine status (pituitary, adrenal function). Disease-free or cure is defined as a normal serum level of calcium and parathyroid hormone. 42, [47] [48] [49] Persistent disease is defined as elevated serum levels of calcium and PTH immediately postoperatively. Recurrent disease is defined as an elevated serum level of calcium and PTH after a postoperative period of at least 6 months or more of normocalcemia.
The Fisher exact test and the Mann-Whitney U test were used for 2-group comparisons. 39 All continuous variables were reported as mean Ϯ standard error of the mean. The probabilities of disease-free survival were calculated and plotted according to the Kaplan-Meier method and compared using the exact log-rank test and the method of Rothman to determine the confidence intervals. 50 Comparisons with the literature were performed using the normal distribution and calculating means plus 2 standard deviations to define the limits for P Ͻ 0.05.
RESULTS
Eighty-four patients with MEN1, HPT, and ZES were studied ( Table 1) . Forty-nine were female (58%). The mean age of onset of the MEN1 was 27 years, the HPT was 31 years, and the ZES was 33 years (Tables 1 and 2). Each patient had elevated serum levels of ionized calcium, total calcium, and PTH with a mean level of 1.52 mmol/L (normal level (nl 1.17-1.31 mmol/L), 2.81 mmol/L (nl 2-2.5 mmol/ L), and 2.43-fold normal, respectively ( Table 2 ). Urinary levels of calcium excretion were also elevated with a mean level of 8.6 mmol for 24 hours. Sixty-two percent had kidney stones. Bone density studies were done in 56 patients (67%) and 25 had decreased bone density (46%) ( Table 2 ). Each patient had MEN1, and 81% had a family history consistent with MEN1, 63% had pituitary tumor, and 34% carcinoid of either the bronchus (14%) or the thymus (7%) ( Table 1) . Each had concomitant ZES with elevated fasting levels of gastrin (8-fold increase over normal) and elevated BAO of 38 mEq/h and MAO of 57 mEq/h (Tables 1 and 2 ). Seventy-nine percent had upper abdominal pain and indigestion, 65% had diarrhea, and 48% had gastroesophageal reflux symptoms.
Fifty-six percent had a peptic ulcer on endoscopy, whereas 20% had prior gastric surgery.
It was a mean of 9 years from the onset of MEN1 and 5 years from the onset of HPT to the time of initial neck surgery for HPT (Table 2) . At the initial operation for HPT, 35 patients (42%) had less than 3 glands removed, 40 (47%) had between 3 and 3.5 removed, whereas 9 had a 4-gland resection with transplant (11%) ( Table 3 ). The mean number of parathyroid glands removed was 2.8. The pathologist diagnosed parathyroid hyperplasia on every parathyroid gland that was removed. The mean follow-up after parathyroid surgery was 7.2 years and 34 (40%) were disease-free, 33 (39%) hypercalcemic, 17 (20%) hypocalcemic, and 44% had an elevated PTH level. If less than 3 parathyroid glands were removed at the initial operation as occurred in 35 patients, the incidence of hypoparathyroidism was 3% and nearly everyone developed either recurrent (46%) or persistent (43%) hypercalcemia for a total of 92%. If between 3 (n ϭ 4 patients) and 3.5 glands (n ϭ 36 patients) were removed, the incidence of hypoparathyroidism was 10% and that of persistent (12%) or recurrent (44%) HPT was a total of 57%. If 4 or more glands were removed, persistent HPT was 0% and recurrent was 22%. Overall, in the 84 patients studied with 16-year follow-up, 24% had persistent disease and 46% had recurrent HPT, whereas 7% were hypoparathyroid ( Table  4 ). The parathyroid disease-free survival for all patients from the original surgical procedure for HPT was 50% at 10 years ( Fig. 1 , upper left panel). If either 3.5 parathyroid glands or † Normal plasma PTH mid molecule and PTH IRMA values are 50 to 340 pg/mL and 10 to 65 before 9/94 and after 9/99. From 9/94 to 9/99 normal values were 9.4 to 49 pg/mL. Values are means from 52 patients taken immediately before the 1st PTX. PTH mid molecule levels are expressed as fold increase over the upper limit of normal to allow comparison of values from other labs. ‡ Fasting serum gastrin levels are from 53 patients who were assessed immediately before and after PTX and expressed as fold increase over the upper limit of normal (ie, 100 pg/mL) to allow comparison from different labs as described previously. 37, 38 § Normal values of urinary calcium are 1.25 to 62.5 mmol/24 h. To convert to mg/24 h multiply by 40.
¶ Bone density studies were performed in 56 patients and the result expressed as the percentage of patients showing any area evaluated with a Z score decreased at less 2SD for age-matched controls.
ZES indicates Zollinger-Ellison syndrome; MEN1, multiple endocrine neoplasia type 1; HPT, hyperparathyroidism; BAO, basal acid output.
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HPT in MEN1 and ZES 4 glands were removed surgically, the disease-free survival was significantly improved (Fig. 1, lower left panel) . In patients with recurrent HPT, the recurrence rate was 50% at 10 years ( Fig. 1 , upper right panel) and there was no difference in time to recurrence between greater and less than 3 glands removed at the initial surgery ( Fig. 1, lower right panel) .
Fasting serum levels of gastrin did not affect the parameters of HPT including ZES onset, age at first surgery for HPT, and surgical parameters (Table 5 ). However, when the biochemical parameters of HPT are corrected with surgery, the biochemical parameters of ZES are dramatically im-proved ( Fig. 2) . When HPT was corrected surgically, serum levels of gastrin, BAO, and delta gastrin level with secretin each significantly improved. Those who underwent parathyroid surgery without correction of hypercalcemia had significantly less changes in their biochemical parameters of ZES post-PTX (Fig. 2) . Specifically, the mean Ϯ standard error of the mean decrease in fasting serum gastrin in the patients with successful PTX was 70% Ϯ 3% versus 35% Ϯ 25% in patients with an unsuccessful PTX, which was significantly different (P ϭ 0.023). Furthermore, in a recent study we sampled fasting serum gastrin on serial days from ZES patients and showed with our assays intra and interassay variations that a significant decrease occurred (P Ͻ 0.05) only with changes greater than 60%. 51 In our study 28% of the patients with an unsuccessful PTX showed such a change on post-PTX follow-up, whereas 74% of the patients with a successful PTX showed such a change, which was significantly different (P ϭ 0.030). The biochemical parameters decreased to such a degree in a number of patients after successful PTX that 20% of patients with MEN1, HPT, and ZES no longer had any biochemical evidence of ZES after surgery to treat HPT without removing any pancreatic or duodenal neuroendocrine tumor.
Laboratory, clinical, and operative findings were analyzed in an attempt to determine factors that may predict the long-term disease-free survival of HPT in patients with HPT, ZES, and MEN1 ( Table 6 ). The diagnosis of ZES as the initial manifestation of MEN1 is associated with a decreased probability of HPT being present at last follow-up (9% vs. 43%, P ϭ 0.0006). If a germline mutation in the Menin gene was detected, there is an increased probability that HPT is present at last follow-up (100% vs. 79%, P ϭ 0.0069). If HPT was diagnosed greater than 28.5 years of age, there was a decreased likelihood of recurrence (39% vs. 61%) (P ϭ 0.045). Finally, if serum calcium levels were increased greater than 110% normal, there was a 78% chance of HPT at last follow-up versus 28% in those with lesser elevations (P ϭ 0.0020) ( Table 6 ).
DISCUSSION
Even though up to 70% of all patients with MEN1 develop ZES in some studies 19, 52 and almost one-half of the patients in an average of 14 series, 19 few, if any, prior studies have focused on parathyroid surgery only in MEN1 patients with HPT and ZES (MEN1/HPT/ZES). These patients have a number of unique features from patients with MEN1/HPT 1, 6, 14, 53, 54 Second, MEN1/HPT patients in the other surgical series were often detected by screening for MEN1 and hence the MEN1/HPT was usually detected at a different time in the natural history of the disease than most MEN1/ HPT/ZES patients. 19, 55 Third, up to 30% of MEN1/ZES patients present with symptoms of the ZES and the HPT may only be recognized later. 19, 41 Therefore, the timing of the initial PTX and its place in the natural history of the MEN1 may differ substantially from patients without ZES. Fourth, the occurrence of the ZES may have an effect on the timing of the PTX in an MEN1 patient, because previous studies in small numbers of patients show that, in some studies, [23] [24] [25] [26] [27] but not others, 26, 28, 29, 34, 35 the PTX with correction of the hypercalcemia may have an ameliorating effect on the acid secretion, responsiveness to antisecretory drugs, fasting gastrin levels, and secretin provocative testing. The current study includes a large number of MEN1/HPT/ZES patients (n ϭ 84) who were prospectively studied. A number of our results supports the conclusion that the HPT in patients with MEN1/HPT/ZES is more severe and more difficult to treat than reported in MEN1/ HPT patients. First, a higher percentage of our patients had a history of neprolithiasis at the time of the initial PTX than reported in the literature in MEN1/HPT patients (62%-our study vs. 40% Ϯ 6%, P Ͻ 0.05, 7 series). 10,14,16,54,56 -58 This finding suggests our patients had more aggressive disease at the time of surgery. Second, in our patients the average serum intact PTH level at the initial PTX was increased to a greater extent than reported in the MEN/ HPT patients in the literature ͓our patients-2.4-fold increase vs. 1.67 Ϯ 0.38 fold in the literature (n ϭ 8 series), P Ͻ 0.05͔. 1,9,53,54,59 -61 These results further support the conclusion that our patients had a more severe form of HPT at the time of the initial PTX. Third, our patients had a mean lower age at the initial PTX than reported in the literature for a series of MEN1/HPT patients (ours-36 years vs. 40.5 Ϯ 1.8 years, P Ͻ 0.05, 10 series). 1, 6, 7, 10, 14, 56, 59, 60, 62 These results demonstrated that the increased severity of the HPT seen in our patients was not due to a later time of presentation in the natural history of the MEN1 of the patients, but instead due to an increased severity of the HPT itself. Fourth, our surgical results demonstrate our recurrence rate after subtotal PTX (3-3.5 glands) was 2.6-fold higher than that reported in the literature for MEN1/HPT patients (our patients-44% vs. literature-16.8%, P Ͻ 0.00001, 15 series; Tables 7 and 8 ). Finally, bone density was decreased in 47% of patients that is also consistent with more severe HPT.
To attempt to identify clinical or laboratory factors that might be predictive for which patients demonstrate more aggressive HPT with a higher recurrence rate, we correlated a number of these factors with the surgical outcome. Four factors that were particularly important and 3 favoring a higher recurrence rate were the occurrence of ZES as the initial symptom, the presence of higher calcium levels pre-PTX, and the presence of a germline MEN1 mutation, whereas a lower recurrence rate was favored by older age of detection of HPT (Ͼ28.5 years old). In 1 study, 60 an important predictor of whether the PTX would control the HPT long-term Eight patients demonstrated a negative secretin test post-PTX using the criterion of Ն200 pg/mL increase postsecretin (shaded area) and 3 patients using the recently proposed criterion of Ն120 pg/mL increase. 37, 38 Norton et al Annals of Surgery • Volume 247, Number 3, March 2008 was the absence of a family history of MEN1. Because a family history is associated with a germline MEN1 mutation detected, 19 this is consistent with our findings. A second study 40 also shows that patients 19 with a positive family history had a more severe form of HPT, which is consistent with our findings. These results suggest these factors will be important on recurrence rates post-PTX in future studies. The effect of PTX on the behavior of the gastrinoma in patients with MEN1/HPT/ZES including fasting gastrin levels, BAO, and secretin provocative testing is controversial in the literature. 26 Some previous studies on small numbers of cases [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] report that PTX in MEN1/HPT/ZES patients can markedly decrease the fasting gastrin levels, BAO, and/or secretin-stimulated gastrin response, whereas a number of other studies report either no effect or a minimal effect on these measures of gastrinoma function. 28, 29, [33] [34] [35] [36] Our study convincingly demonstrates the marked ameliorating effect of a successful PTX on these parameters, because we were able to study a larger number of patients and correlate the changes in gastrinoma function with the outcome of the PTX (Fig. 2) . In fact, some patients (20%) with MEN1/HPT/ZES no longer had biochemical evidence of ZES with surgery not directed at the pancreatic neuroendocrine tumor, but to remove only the abnormal parathyroid glands. These data are similar to what we previously reported in 1987 23 ; however, in that study a higher proportion of patients were cured. The prior study had fewer patients with shorter follow-up that may explain the increase in cure-rate. These findings are even more important when we remember that surgery to remove the gastrinoma in MEN1 patients seldom affects the parameters of ZES. 19, 20, 39, 65 In fact, ZES in these patients is seldom cured by surgery to remove the gastrinoma because the tumors are often multiple within the duodenum and pancreas, and frequently associated with lymph node metastases. 21, [65] [66] [67] This further supports the strategy that parathyroid surgery should be performed first before any abdominal surgery for ZES.
Previously it was reported that the HPT in patients with MEN1 is always hyperplasia and the operation of choice is either 3.5-gland PTX or 4-gland PTX with transplant. [11] [12] [13] 16, 17 The current study corroborates the presence of multiple gland disease in MEN1/HPT/ZES patients and the need for extirpation of at least 3 or more glands. In fact, when this was accomplished patients had a longer disease-free interval, but not a lower incidence of recurrent hypercalcemia (Fig. 1) . Recurrent HPT is explained by the pathophysiology of the HPT in these patients, whereas persistent HPT is explained by the extent of the surgery. Recurrent HPT depends on the subsequent growth of residual abnormal parathyroid glands, whereas persistent HPT is more common if less than 3 glands are excised. From our results, the 4-gland resection and transplant is not recommended because there was a high graft failure rate and therefore an unacceptable rate of hypoparathyroidism. Furthermore, most studies on MEN1/HPT patients 5, 6, 46, 59, 68, 69 demonstrate a low rate (0%-13% of pa- 70, 71 of autonomous hyperfunction with time in the transplanted parathyroid glands resulting in recurrent HPT. We found that in the MEN1/HPT/ZES patients this was not an infrequent outcome, occurring in 44% of our patients with a 4-gland resection and an implant. This finding supports the contention that the parathyroid disease in patients with MEN1/HPT/ZES is severe. Recurrent HPT due to the graft has previously been felt to make reoperation easier 53 ; however, forearm reoperations have been more difficult than previously anticipated (personal observation). Large amounts of forearm muscle may need to be excised to remove the embedded abnormal parathyroid tissue. Therefore, it seems best to leave a small amount of parathyroid tissue within the neck and mark it with a clip so that, if necessary, it can subsequently be found and either excised or trimmed.
In summary, our studies support the conclusion that patients with MEN1, HPT, and ZES represent a unique subgroup of patients with a more virulent form of HPT. In these patients there is no ideal surgical procedure to control the hypercalcemia and ameliorate the symptoms. This is because the HPT is caused by diffuse hyperplasia of all the parathyroid glands even though at times it may be asymmetric. Currently, the 3.5-gland PTX is recommended as the best surgical procedure. It is associated with a prolonged diseasefree interval in many patients and a low incidence of hypoparathyroidism. Furthermore, 3.5-gland resection corrects the hypercalcemia and impacts favorably on the biochemical parameters of ZES. However, our study demonstrates that these patients need particularly careful follow-up as they have a high recurrence rate. Increased severity of HPT Higher frequency of nephrolithiasis at presentation ͓62% vs. 40% Ϯ 6% (7 series, literature), P Ͻ 0.05͔* Higher serum PTH levels at presentation ͓2.4-fold normal vs. 1.67 Ϯ 0.38 (8 series, literature), P Ͻ 0.05͔* Higher relapse rate post subtotal PTX ͓44% vs. 17%, P Ͻ 0.00001 (15 series, literature)͔ † Predictive factors for increased recurrence post subtotal PTX ‡ ZES initial clinical manifestation of MEN1 (P ϭ 0.0006) Presence of MEN1 germline mutation (P ϭ 0.0069) HPT diagnosed Ͻ28.5 yr of age (P ϭ 0.045) Serum calcium levels at presentation Ͼ110% normal (P ϭ 0.0020) *References for literature series in text. † References in Table 7 . ‡ Data from analysis in Table 6 .
